Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits viral RNA polymerase
|
| gptkbp:age |
not recommended for children under 12
|
| gptkbp:approves |
gptkb:Japan
gptkb:United_States |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Xofluza
|
| gptkbp:category |
gptkb:unknown
gptkb:C |
| gptkbp:clinical_trial |
Phase III
acute uncomplicated influenza ongoing studies for other viruses |
| gptkbp:contraindication |
hypersensitivity to baloxavir
|
| gptkbp:developed_by |
gptkb:Shionogi
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
one dose
|
| gptkbp:education |
inform about potential side effects
|
| gptkbp:effective_date |
gptkb:2018
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
single-dose oral tablet
|
| gptkbp:healthcare |
important for appropriate use
potential to reduce flu burden |
| https://www.w3.org/2000/01/rdf-schema#label |
baloxavir
|
| gptkbp:ingredients |
C19 H18 F2 N2 O3 S
|
| gptkbp:interacts_with |
minimal drug interactions
|
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
J05 AX
|
| gptkbp:is_effective_against |
comparable to oseltamivir
reduces duration of flu symptoms |
| gptkbp:is_used_for |
treatment of influenza
|
| gptkbp:lifespan |
approximately 19 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Xofluza
|
| gptkbp:metabolism |
primarily hepatic
|
| gptkbp:pharmacokinetics |
rapid absorption
inhibits cap-dependent endonuclease activity |
| gptkbp:population |
adults and adolescents
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
recommended for high-risk patients
CDC recommends for certain populations |
| gptkbp:publishes |
numerous peer-reviewed articles
|
| gptkbp:research_areas |
multiple global research centers
|
| gptkbp:research_focus |
influenza treatment efficacy
|
| gptkbp:safety_features |
generally well tolerated
post-marketing surveillance ongoing |
| gptkbp:side_effect |
headache
nausea vomiting diarrhea rare serious adverse reactions |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
gptkb:virus
|
| gptkbp:transmission |
may reduce transmission of influenza
|
| gptkbp:treatment |
within 48 hours of symptom onset
|
| gptkbp:type_of |
1985604-12-0
|
| gptkbp:water_resistance |
low resistance rates observed
|
| gptkbp:bfsParent |
gptkb:influenza_B_virus
|
| gptkbp:bfsLayer |
6
|